糖脉康颗粒联合格列美脲治疗2型糖尿病的临床研究
|
摘要
目的探究糖脉康颗粒联合格列美脲片治疗2型糖尿病的临床疗效。方法选取2016年5月—2017年9月乌鲁木齐市友谊医院收治的102例2型糖尿病患者为研究对象,全部患者随机分为对照组和治疗组,每组各51例。对照组早餐前服用格列美脲片,1～4 mg/d;治疗组在对照组基础上口服糖脉康颗粒,5 g/次,3次/d。两组均连续治疗8周。观察两组的临床疗效,比较两组的血糖水平、血脂水平和炎症指标。结果治疗后,对照组和治疗组的总有效率分别为76.47%、92.16%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者空腹血糖(FPG)、餐后2 h血糖(2 h PBG)和糖化血红蛋白(HbA1c)水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组FPG、2 h PBG、HbA1c水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平显著降低,高密度脂蛋白胆固醇(HDL-C)水平明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组TG、TC、LDL-C水平较对照组明显下降,HDL-C水平较对照组明显上升,同组治疗前后比较差异有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、IL-6水平均明显下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组hs-CRP、IL-6水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论糖脉康颗粒联合格列美脲片治疗2型糖尿病具有较好的临床疗效,可改善其血糖血脂水平,降低炎症反应,具有一定的临床应用价值。
Objective To explore the clinical effect of Tangmaikang Granules combined with Glimepiride Tablets in treatment of type2 diabetes. Methods Patients(102 cases) with type 2 diabetes in Urumqi Friendship Hospital from May 2016 to September 2017 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Glimepiride Tablets before breakfast, 1 — 4 mg/d. Patients in the treatment group were po administered with Tangmaikang Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks.After treatment, the clinical efficacies were evaluated, and blood glucose level, blood lipid level, and inflammatory indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.47% and 92.16%,respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of FPG, 2 h PBG, and HbA1 c in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the blood glucose levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of TG, TC, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of hs-CRP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the inflammatory indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Tangmaikang Granules combined with Glimepiride Tablets has clinical curative effect in treatment of type 2 diabetes, can improve the level of blood sugar and lipid, and reduce the inflammatory reaction, which has a certain clinical application value.
Objective To explore the clinical effect of Tangmaikang Granules combined with Glimepiride Tablets in treatment of type2 diabetes. Methods Patients(102 cases) with type 2 diabetes in Urumqi Friendship Hospital from May 2016 to September 2017 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Glimepiride Tablets before breakfast, 1 — 4 mg/d. Patients in the treatment group were po administered with Tangmaikang Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks.After treatment, the clinical efficacies were evaluated, and blood glucose level, blood lipid level, and inflammatory indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.47% and 92.16%,respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of FPG, 2 h PBG, and HbA1 c in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the blood glucose levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of TG, TC, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of hs-CRP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the inflammatory indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Tangmaikang Granules combined with Glimepiride Tablets has clinical curative effect in treatment of type 2 diabetes, can improve the level of blood sugar and lipid, and reduce the inflammatory reaction, which has a certain clinical application value.
引文
[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[2]梁峰,胡大一,沈珠军.2014美国糖尿病指南:糖尿病诊疗标准[J].中华临床医师杂志:电子版,2014,8(6):151-159.
[3]胡嫚丽,邓红艳,符杰,等.糖脉康颗粒对2型糖尿病患者血糖水平的影响[J].中国实验方剂学杂志,2015,21(14):173-176.
[4]郑筱萸.中药新药临床研究指导原则(试行)[J].北京:中国医药科技出版社,2002:236-237.
[5]田佳星,赵林华,连凤梅,等.中医药防治糖尿病研究进展述评[J].中医杂志,2015,56(24):2093-2097.
[6]高娜.中西医结合治疗2型糖尿病临床疗效及安全性分析[J].河北中医,2016,38(2):228-230,242.
[7]袁群,俞璐,邵致格,等.糖脉康颗粒对2型糖尿病患者胰岛素敏感性的临床疗效观察[J].中国临床药理学杂志,2015,31(12):1099-1102.
[8]张艾萍,杨文.2型糖尿病及合并并发症患者主要生化指标分析[J].重庆医学,2017,46(21):2943-2944.
[9]吴深涛.糖尿病中医病机新识[J].中国中医基础医学杂志,2005,11(11):808-811.
[10]Annuzzi G,Bozzetto L,Patti L,et al.Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response:a possible link with diabetic postprandial dyslipidemia[J].Metabolism,2010,59(4):567-574.
[11]梁懿玑.2型糖尿病血糖与炎症因子相关性分析[J].实用妇科内分泌杂志:电子版,2017,4(27):83,86.
[2]梁峰,胡大一,沈珠军.2014美国糖尿病指南:糖尿病诊疗标准[J].中华临床医师杂志:电子版,2014,8(6):151-159.
[3]胡嫚丽,邓红艳,符杰,等.糖脉康颗粒对2型糖尿病患者血糖水平的影响[J].中国实验方剂学杂志,2015,21(14):173-176.
[4]郑筱萸.中药新药临床研究指导原则(试行)[J].北京:中国医药科技出版社,2002:236-237.
[5]田佳星,赵林华,连凤梅,等.中医药防治糖尿病研究进展述评[J].中医杂志,2015,56(24):2093-2097.
[6]高娜.中西医结合治疗2型糖尿病临床疗效及安全性分析[J].河北中医,2016,38(2):228-230,242.
[7]袁群,俞璐,邵致格,等.糖脉康颗粒对2型糖尿病患者胰岛素敏感性的临床疗效观察[J].中国临床药理学杂志,2015,31(12):1099-1102.
[8]张艾萍,杨文.2型糖尿病及合并并发症患者主要生化指标分析[J].重庆医学,2017,46(21):2943-2944.
[9]吴深涛.糖尿病中医病机新识[J].中国中医基础医学杂志,2005,11(11):808-811.
[10]Annuzzi G,Bozzetto L,Patti L,et al.Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response:a possible link with diabetic postprandial dyslipidemia[J].Metabolism,2010,59(4):567-574.
[11]梁懿玑.2型糖尿病血糖与炎症因子相关性分析[J].实用妇科内分泌杂志:电子版,2017,4(27):83,86.